

## PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
XTL Biopharmaceuticals Ltd.	01/09/2008
RECEIVING PARTY DATA	
Name:	Yeda Research and Development Company Limited
Street Address:	Weizman Institute of Science
Internal Address:	P.O. Box 95
City:	Rehovot
State/Country:	ISRAEL
Postal Code:	76100
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11911939
CORRESPONDENCE DATA	
Fax Number:	(858)450-8499
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	858-450-8400
Email:	Les.Overman@HellerEhrman.com
Correspondent Name:	Leslie B. Overman, Heller Ehrman LLP
Address Line 1:	4350 La Jolla Village Drive
Address Line 4:	San Diego, CALIFORNIA 92122
ATTORNEY DOCKET NUMBER:	23135-0038 (YEDA)
NAME OF SUBMITTER:	Leslie B. Overman
Total Attachments: 2	
source=XTL to Yeda assignment#page1.tif	
source=XTL to Yeda assignment#page2.tif	

CH \$40.00 11911939

500438237

PATENT  
REEL: 020356 FRAME: 0598

## **ASSIGNMENT**

XTL BIOPHARMACEUTICALS, LTD., having a place of business at Kiryat Weizmann Science Park, Bldg. 3, POB 370, Rehovot, 76100, Israel, for good and valuable consideration, have assigned and do hereby assign to YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED, having a place of business at the Weizmann Institute of Science, POB 95, Rehovot, 76100, Israel, its successors, assigns and legal representatives, the entire right, title and interest in and to all subject matter disclosed in the application for Letters Patent of the U.S. Patent Application No. 11/911,939, filed on October 18, 2007, entitled:


### **STABILIZED ANTI-HEPATITIS B (HBV) ANTIBODY FORMULATIONS**

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

XTL BIOPHARMACEUTICALS, LTD. agrees to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.

DATE: Jun. 9, 2008

XTL BIOPHARMACEUTICALS, LTD.

  
Name: Ron Bentler  
Title: CEO

WITNESSED:

DATE: Jan 9, 2008

  
[SIGNATURE OF WITNESS]

PAM WALISBOYD  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: 1-9-2008

  
[SIGNATURE OF WITNESS]

ROMEO A. CRUZ  
[PRINTED NAME OF WITNESS]